Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
HOME > LATEST
LATEST
-
ORGANIZATION Ex-MHLW Official Isobe, Now at Self-Medication Group, Touts OTC Use to Soften Impact of Off-Year Re-Pricing
September 7, 2022
-
REGULATORY Japan to Roll Out Pilot Program for SaMD Priority Review System
September 7, 2022
-
BUSINESS Sysmex Files Gene Profiling Test as CDx for Taiho’s Futibatinib
September 7, 2022
-
BUSINESS Opdivo Best-Selling Drug in Japan for 8 Months on End: Encise
September 7, 2022
-
BUSINESS Pfizer Japan to Stop Amoxapine Shipments, Start Recall in February after Carcinogen Detection
September 7, 2022
-
REGULATORY Ultrasound Dementia Therapy Machine in Line for First Sakigake Device Designation, Japan Submission Eyed in 2025
September 6, 2022
-
REGULATORY MHLW Study Group to Ponder Support Measures for Stable Generic Supplies
September 6, 2022
-
BUSINESS Tatsumi Kagaku Likely to Halt Shipments of 46 Products after Administrative Penalty
September 6, 2022
-
BUSINESS Moderna to File BA.4/5-Targeting Booster Jab in Japan
September 6, 2022
-
BUSINESS Teijin Gets Approval for 14-Day Version of Osteoporosis Med Ostabaro
September 6, 2022
-
REGULATORY Japan Govt to Start Omicron Vaccine Distribution from Week of Sept. 19
September 6, 2022
-
REGULATORY Tatsumi Kagaku Faces Biz Improvement Order over Discrepant Manufacturing Method, Falsified Records
September 5, 2022
-
REGULATORY METI Seeks 7 Billion Yen to Develop Next-Gen Drug Discovery Tech Platform: FY2023 Budget Request
September 5, 2022
-
REGULATORY No Major Safety Concerns for COVID-19 Vaccines in Japan: MHLW Panels
September 5, 2022
-
ORGANIZATION Chuikyo Payer Rep Eyes 5%-Plus Discrepancy Threshold or Broader Coverage: 2023 Off-Year Re-Pricing
September 5, 2022
-
ACADEMIA Academic Societies Urge Japan Govt to Approve Shionogi’s COVID-19 Pill
September 5, 2022
-
REGULATORY Japan to Give Omicron Boosters to Elderly from Mid-September
September 5, 2022
-
COLUMN The Evolving US Managed Care Environment and Implications of US Market Attractiveness for Japanese Manufacturers
September 5, 2022
-
BUSINESS Leo Pharma Japan Names Finance Head Kook Hyun Son as Interim Chief
September 2, 2022
-
BUSINESS Nitrosamine Impurity Detected in Sitagliptin, Shipments in Japan to Continue with FDA-Set Limit: MSD/Ono
September 2, 2022
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…